The Canadian-based company is dedicated to developing, manufacturing, and commercializing novel medicines that address major unmet medical needs, with a particular focus on oncology. Their anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta has submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA and is seeking marketing approval to make MCNA available for patients and their physicians. Their ultimate goal is to transform the treatment landscape and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.